Canadian Halal Investor.

TSX Shariah screener · September 2026

Is Cronos Group (CRON) Halal?

FAIL

Cronos Group Inc. · TSX: CRON / NASDAQ: CRON · Healthcare

The short answer

Cronos Group Inc. (TSX: CRON) is a FAIL. The business gate fails: adult-use (recreational) cannabis - led by the Spinach brand in Canada - is about US$28.7M of US$53.0M Q2 2026 net revenue (~54%), far above the 5% tolerance; the sale of intoxicants is a prohibited business activity under AAOIFI-style screening. The income gate fails: Q2 2026 "Interest income, net" of US$8,816K is about 16.6% of US$53,007K net revenue, above the ~5% ceiling. The cash gate fails: cash, short-term investments and interest-bearing deposits of US$827.0M at June 30, 2026 are about 66.4% of the ~US$1.25B market cap (US$3.38, September 29, 2026, on 368,412,864 shares) - against a ~33% ceiling. The debt gate passes: no interest-bearing debt is reported (the company describes its balance sheet as debt-free). Musaffa independently rates CRON.TO not halal (September 2026); no public Zoya rating or ShariaPortfolio coverage was found. As with every screener here, this is a rules-based screening of published figures, not a religious ruling - consult a qualified scholar for personal guidance.

Gate 1 — Business activity: FAIL

Cronos Group Inc. is a Toronto-based global cannabis company cultivating, manufacturing and marketing cannabis for medical and adult-use markets in Canada, Israel and Germany, with brands including Spinach, PEACE NATURALS, LIT and Lord Jones. For Q2 2026 (three months ended June 30, 2026) it reported record net revenue of US$53,007K: Israel US$15.0M (medical cannabis, 10th consecutive record quarter), international markets outside Israel US$9.3M (led by Germany, medical), and Canada about US$28.7M - where Spinach maintained the #1 position in vapes and edibles, adult-use recreational products. Adult-use (recreational) cannabis therefore accounts for roughly 54% of net revenue - far above the 5% non-compliant-revenue tolerance, so the business gate fails on the same basis as this site's Canopy Growth screen (adult-use ~29% of revenue). Medical cannabis in Israel and Germany (~46% of revenue) is a separate question for a qualified scholar. Facts only, no fatwa.

Gate 2 — Debt and cash: FAIL (cash)

Cronos reports no interest-bearing debt - the company describes its balance sheet as debt-free - so the debt-to-market-cap ratio is about 0%, under the ~33% ceiling; the debt component passes. The cash component fails. The Q2 2026 balance sheet shows cash and cash equivalents US$467,019K, short-term investments US$330,000K and non-current interest-bearing deposits US$30,000K - US$827,019K in total, the US$827M treasury reserve highlighted in the August 6, 2026 results release. Against a market capitalization of about US$1.25B (US$3.38, September 29, 2026, on 368,412,864 shares outstanding at August 3, 2026), that is about 66.4% - above the ~33% ceiling. Excluding the US$30M of non-current deposits, the ratio is still about 64.0%. The cash gate fails.

Gate 3 — Non-compliant income: FAIL

The Q2 2026 10-Q discloses "Interest income, net" of US$8,816K against net revenue of US$53,007K - about 16.6%, above the ~5% ceiling. The income gate fails - the company's large treasury reserve generates interest income at a level that alone exceeds the tolerance.

Key figures used

Frequently asked questions

Is Cronos Group (CRON) halal?

Our September 2026 screen gives Cronos Group Inc. (TSX: CRON, NASDAQ: CRON) a FAIL. The business gate fails: adult-use (recreational) cannabis - led by the Spinach brand in Canada - accounts for a clear majority of revenue, about US$28.7M of US$53.0M net revenue (~54%) in Q2 2026, far above the 5% tolerance; the sale of intoxicants is a prohibited business activity under AAOIFI-style screening. The income gate fails: Q2 2026 'Interest income, net' of US$8,816K is about 16.6% of US$53,007K net revenue, above the ~5% ceiling. The cash gate fails: cash and cash equivalents plus short-term investments and interest-bearing deposits of US$827.0M at June 30, 2026 are about 66.4% of the ~US$1.25B market cap (US$3.38, September 29, 2026, on 368,412,864 shares) - against a ~33% ceiling. The debt gate passes: no interest-bearing debt is reported (the company describes its balance sheet as debt-free), about 0% of market cap. Musaffa independently rates CRON.TO not halal (September 2026); no public Zoya rating or ShariaPortfolio coverage was found. This is a rules-based screening of published figures, not a religious ruling.

What business is Cronos Group in?

Cronos Group Inc. is a Toronto-based global cannabis company cultivating, manufacturing and marketing cannabis for medical and adult-use markets in Canada, Israel and Germany, with brands including Spinach, PEACE NATURALS, LIT and Lord Jones. For Q2 2026 (three months ended June 30, 2026) it reported record net revenue of US$53,007K: Israel US$15.0M (medical cannabis, 10th consecutive record quarter, PEACE NATURALS the #1 brand), international markets outside Israel US$9.3M (led by Germany, medical), and Canada about US$28.7M, where Spinach maintained the #1 position in vapes and edibles - adult-use recreational products. A pending acquisition of Netherlands-based cannabis producer CanAdelaar B.V. is expected to close in the second half of 2026.

Why does Cronos fail the business gate?

The business gate fails because adult-use (recreational) cannabis is a core business line, not a trace exposure. In Q2 2026, Canada - where Cronos's sales are led by the adult-use Spinach brand (#1 in vapes and edibles nationally) - contributed about US$28.7M of US$53.0M net revenue (~54%), far above the 5% non-compliant-revenue tolerance this screening uses. Under AAOIFI-style screening, the sale of intoxicants is a prohibited business activity; this is the same basis on which this site's Canopy Growth screen failed (adult-use cannabis ~29% of revenue). Medical cannabis (Israel and Germany, ~46% of revenue) is a separate question for a qualified scholar; the business-gate result rests on the recreational share alone. Facts only, no fatwa.

Why does Cronos fail the income and cash gates?

Cronos sits on one of the largest cash piles in the cannabis sector, and that cash generates substantial interest income. The Q2 2026 10-Q reports 'Interest income, net' of US$8,816K against net revenue of US$53,007K - about 16.6%, above the ~5% ceiling, so the income gate fails. The balance sheet at June 30, 2026 shows cash and cash equivalents US$467,019K, short-term investments US$330,000K and non-current interest-bearing deposits US$30,000K - US$827,019K in total, the US$827M treasury reserve highlighted in the August 6, 2026 results. Against a market capitalization of about US$1.25B (US$3.38, September 29, 2026, on 368,412,864 shares), that is about 66.4% - above the ~33% ceiling, so the cash gate fails. Even excluding the US$30M of non-current deposits, the ratio is about 64.0%. The debt gate passes: no interest-bearing debt is reported.

What do Zoya, Musaffa or ShariaPortfolio say about CRON?

Musaffa rates Cronos Group (CRON.TO) not halal as of September 2026 under its AAOIFI methodology - consistent with this screen's overall FAIL. No public Zoya rating for CRON was found: zoya.finance has no CRON stock page (it returned HTTP 404 when checked directly in September 2026). ShariaPortfolio publishes no per-stock screening tool, so no coverage exists there. The per-gate figures behind this screen's result come from Cronos's own Q2 2026 10-Q and the August 6, 2026 results press release. Other cannabis names on this site - Aurora Cannabis (FAIL, September 2026) and Canopy Growth (FAIL) - are screened on the same business, debt, cash and income basis.

Sources

Screened 2026-09-30 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.